Paclitaxel (Taxol) is an antineoplastic agent that specifically targets microtubules and arrests cells at the G2/M phase of the cell cycle. In addition to mitotic arrest, the activation of c-Jun N-terminal kinase (JNK) signaling pathway has been demonstrated to be involved in the process leading to apoptosis. In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125. Among 20 genes that were specifically regulated by the paclitaxel-activated JNK pathway, interleukin (IL)-6 was shown to elicit function through the JAK-STAT signaling pathway in an autocrine and/or paracrine fashion. Subsequently, we identified that 87.5% of eight tested ovarian cancer lines secreted detectable levels of IL-6, which could be further upregulated 2-3.2 fold by 1 lM paclitaxel. Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 lM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 lM), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway. Collectively, these results suggest that paclitaxel upregulates functional IL-6 expression in human ovarian cancer cells through multiple signaling pathways.
Introduction
Paclitaxel (Taxol) has been proven effective for treating a wide range of solid tumors, including those caused by ovarian, breast, lung and prostate cancers (Taxman et al., 2003; Jordan and Wilson, 2004) . At clinically achievable concentrations from several hundred nanomolar to 3 mM, the best-characterized cellular target of paclitaxel are the microtubules (Blagosklonny and Fojo, 1999) . In addition to its stabilizing effects on the microtubules and the subsequent cell cycle arrest in the G2-M phase, paclitaxel also induces the vast activation of signal-transduction pathways that may be associated with proapoptotic signaling (Blagosklonny and Fojo, 1999; Taxman et al., 2003) . Among the proapoptotic signaling networks activated by paclitaxel (Meikrantz and Schlegel, 1996; Lee et al., 1997) , the c-Jun Nterminal kinase (JNK) signaling pathway played an important role (Lee et al., 1998; Wang et al., 1999 Wang et al., , 2000 MacKeigan et al., 2000; Vivat-Hannah et al., 2001; Mingo-Sion et al., 2004) .
To explore what genes are transcriptionally regulated by the activated JNK signaling pathway after paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel in the absence or presence of the JNK inhibitor SP600125 (Bennett et al., 2001) . Among the genes that were specifically upregulated by the paclitaxel-activated JNK pathway, interleukin (IL)-6 was at the top of the list.
Spontaneous production of IL-6 has been observed in various tumors, including ovarian cancer (Watson et al., 1990; Li et al., 1992) , hepatocarcinoma (Baffet et al., 1991) , myeloma cells (Villunger et al., 1996) , head and neck cancer (Sriuranpong et al., 2003) and cervical cancer (Wei et al., 2003) . Specifically for ovarian cancers, upregulation of IL-6 has been associated with pathogenesis (Hefler et al., 2003; Liu et al., 2004) , tumor progression (Fang et al., 2004) , antiapoptosis (Yusuf et al., 2003) , drug resistance (Duan et al., 1999) , patients' poor outcomes (Penson et al., 2000) and paclitaxel-related side effects (Pusztai et al., 2004) . However, the regulatory mechanisms of IL-6 expression in ovarian cancer cells and paclitaxel activation of IL-6 remain unclear.
Treatment of macrophage-like cells with high concentrations (5-30 mM) of paclitaxel has been reported to exert endotoxin lipopolysaccharide (LPS)-like effects, including the upregulation of various cytokines (Ding et al., 1990; Lee et al., 1996; Lanni et al., 1997) . More recently, Toll-like receptor 4 (TLR4) on murine macrophage has been shown to be the receptor for paclitaxel (Kawasaki et al., 2000 (Kawasaki et al., , 2003 Perera et al., 2001) . Paclitaxel, notably at 5-30 mM, was thus proposed as a TLR4 ligand (Takeda et al., 2003) . One of the nuclear targets in the TLR-mediated signaling pathway is NF-IL6, a member of the C/EBP family of transcription factors (Tanaka et al., 1995) . NF-IL6 was originally identified as a transcription factor that specifically binds to an IL-1 responsive element in the IL-6 gene promoter (Akira et al., 1990) , and was subsequently shown to play an important role in LPS-induced gene expression in macrophages (Gorgoni et al., 2001; Uematsu et al., 2002) .
To further understand the mechanisms by which paclitaxel upregulates IL-6, we dissected multiple potential signaling pathways. Our results indicated that IL-6 elicited function through the JAK-STAT signaling pathway and that at least two signaling pathways, which vary depending on the concentration of paclitaxel, might be involved in the upregulation of IL-6.
Results

SP600125
inhibited the phosphorylation of c-Jun by paclitaxel-activated c-Jun N-terminal kinase Consistent with the results of previous studies (Wang et al., 1999 (Wang et al., , 1998 , a 2-h treatment of paclitaxel at concentrations that ranged from 0.1 to 10 mM activated JNK in BR ovarian cancer cells. This can be seen by the phosphorylation of JNK (Figure 1a, upper panel) . When BR cells were treated with 1 mM paclitaxel, phosphorylation of JNK was obvious within 2 h and lasted for at least 24 h (Figure 1a , lower panel). Onehour dose-dependent pretreatment of BR cells with the JNK inhibitor SP600125 inhibited the activity of JNK. This is shown through the inhibition of JNK phosphorylation on c-Jun (Figure 1b, upper panel) . Reports show that JNK inhibition by SP600125 could be due to its MKK4 inhibitory activity or inhibition of JNK autophosphorylating activity (Bennett et al., 2001) . Similarly, SP600125 interfered with phosphorylation of paclitaxelactivated JNK (Figure 1b, lower panel) . Inhibition of c-Jun phosphorylation by SP600125 was functional through AP1, as shown by the inhibition of paclitaxelactivated AP1 reporter through SP600125 treatment (Figure 1c ).
SP600125 10 mM at decreased paclitaxel-induced apoptosis without changing the cell cycle profiles of treated cells Pretreatment with SP600125 for 1 h and the continuous presence of SP600125 in the culture medium inhibited paclitaxel-induced cell death, as shown by the decreased percentage of Trypan-blue stained cells (Figure 2a ) and cleavage of poly (ADP-ribose) polymerase (PARP) (Figure 2b ). These findings were also supported by the results of the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and terminal deoxynucleotidyl transferase biotin-dUPT nick end labeling (TUNEL) assays (data not shown). Although SP600125 has been shown to prolong mitotic progression (Du et al., 2004) and cause G2/M arrest (Mingo-Sion et al., 2004) , we identified that 10 mM SP 600125 did not significantly interfere with paclitaxel-induced cell cycle profile change (Figure 2c and d) . Nonetheless, 20 mM SP 600125 did change the cell cycle profiles (data not shown). Results were obtained from three independent experiments and are presented as mean7standard error (s.e.m.). All fold changes were normalized with the AP1 activity in dimethylsulphoxide-treated BR cells, which was set as 1.
Therefore, we carried out the following experiments with 10 mM SP 600125.
Paclitaxel-activated c-Jun N-terminal kinase transcriptionally regulated multiple genes Analysis of gene expression with DNA microarray was carried out using a loop design (Figure 3a) with the GMRCL Human 7K version 2 microarrays (Wang et al., 2004; Lee et al., 2005) . The loop design was used to integrate results from two independent experiments and to balance potential bias from dye labeling (Churchill, 2002) . Using the criteria Po0.001 (t-test) and fold change of gene expression >1.25, 148 differentially expressed genes were selected from the comparison between the control and the cells treated with paclitaxel (PTX alone); 110 genes were selected from the comparison between the cells treated with 1 mM paclitaxel for 24 h (PTX alone) and the cells pretreated with 10 mM SP600125 for 1 h followed by 1 mM paclitaxel for 24 h (both Tx); and 121 genes were selected from the comparison between the control and the cells only treated with 10 mM SP600125 alone for 25 h (SP alone) (Figure 3b) . Expression of 23 genes was significantly changed by treatment with paclitaxel. These changes could be counteracted by simultaneous treatment with SP600125 (Table 1) . Like all kinase inhibitors, although it is believed that there is high specificity of SP600125 for JNK inhibition, its interference with other signaling pathways cannot be completely ruled out (Bain et al., 2003) . Therefore, three genes (ANXA3, SNK and PLOD2), whose expression was significantly changed by treatment with SP600125 alone, were considered to be regulated by other signaling pathways in addition to the JNK pathway, and received no further analysis in this study (Figure 3b and Table 1 ). The remaining 20 1 mM paclitaxel for 24 h; SP: 10 mM SP600125 for 25 h; Both Tx: pretreatment with 10 mM SP600125 for 1 h followed by a simultaneous treatment with 1 mM PTX and 10 mM SP600125 for 24 h, as indicated. Total RNA was isolated from two independent experiments and subjected to cDNA microarrays for gene expression analysis using a loop design (each arrow represents the use of a microarray slide) with dye swapping strategy (shown as each pair of counter-directional arrows) (Churchill, 2002) . (b) Selecting criteria were Po0.001 (t-test) and fold change of gene expression >1.25. The numbers indicate the number of genes in each subgroup.
Mechanisms of IL-6 upregulation by paclitaxel T-H Wang et al genes included 14 that were upregulated and six that were downregulated by paclitaxel-activated JNK (Table 1 ). The expression changes in these genes identified by microarray analysis were confirmed by real-time quantitative PCR (RT-Q-PCR) (data not shown).
c-Jun N-terminal kinase-dependent secretion of functional interleukin-6 by ovarian cancer cells was increased by treatment with paclitaxel Among the genes upregulated by the paclitaxel-activated JNK pathway (Table 1) , IL-6 stood out in a 3.57-fold change of gene expression and statistical significance (P ¼ 0.000038). Using RT-Q-PCR, we identified the time course of IL-6 upregulation caused by treating BR ovarian cancer cells with 1 mM paclitaxel ( Figure 4a ). We also identified the 24-h basal secretion amount of IL-6 in seven out of eight tested ovarian cancer cells: Caov3, 16257218; TOV-21G, 1054766; SKOV3, 375716; MDAH2774, 130716; BR, 105722; OVCAR3, 8377; OV90, 470.23 (pg/1000 cells, mean7s.e.m., n ¼ 3), with the only exception of undetectable IL-6 level in TOV-112D cells (Figure 4b ). Interleukin-6 secretion in these seven ovarian cancer cell lines could be further upregulated by 2-3.2-fold with treatment of 1 mM paclitaxel (Figure 4b ). Treatment with 1 mM paclitaxel for 24 h increased more than threefold STAT reporter activity, and the activation of STAT reporter could be significantly inhibited by knockdown of IL-6 with specific siRNA (Po0.01) or by co-treatment with 10 mM SP600125 (Po0.05) (Figure 4c ). The ability of siRNA to cause a loss of function was also confirmed by identifying the reduction of IL-6 mRNA levels through RT-Q-PCR (data not shown). Treatment with various concentrations of paclitaxel stimulated the secretion of IL-6 by BR cells into the culture media, and the stimulation could be suppressed by co-treatment with JNK inhibitor SP600125 or by knockdown of JNK1 with short hairpin RNA (shRNA) expression vectors ( Figure 4d) . Surprisingly, the dose-response study revealed that upregulation of IL-6 expression could not be saturated by increasing concentrations of paclitaxel up to 50 mM (Figure 4d ). Therefore, we speculated that multiple regulatory pathways might be involved. Treatment with recombinant human IL-6 (Panomics, CA, USA) at 700 pg/ml concentration, a comparable concentration of IL-6 in culture media of BR cells treated with paclitaxel for 24 h, also activated STAT reporter to a similar extent (3.670.4-fold, mean7s.e.m., n ¼ 2), further confirming that this concentration range of IL-6 was functional to BR cells in an autocrine/paracrine fashion (data not shown).
Paclitaxel at 1 mM upregulated interleukin-6 expression through the c-Jun N-terminal kinase signaling pathway Treatment with 1 mM paclitaxel induced significant activation of both AP1 and STAT3 reporter activity (Po0.05), and a 1.770.3-fold (mean7s.e.m., n ¼ 3, P ¼ 0.149) activation of NF-kB reporter ( Figure 5 ). Interestingly, a seemingly biphasic trend in doseresponse was detected: the AP1 activation by 50 mM paclitaxel was significantly higher than that activated by 0.1-30 mM paclitaxel (Po0.05) (Figure 5a ) and the Mechanisms of IL-6 upregulation by paclitaxel T-H Wang et al NF-kB activation by 50 mM paclitaxel was significantly higher than those activated by 0.1-10 mM of paclitaxel (Po0.05) (Figure 5b ). However, the biphasic trend was not observed in the activation of STAT3 reporter ( Figure 5c ). We also analysed the changes of TLR4-related genes that were spotted in our microarrays. No significant change in the gene expression of TLR4, MyD88 and NF-IL6 was exhibited after treatment with 1 mM paclitaxel (Figure 6a ). The lack of expressional changes in these genes was confirmed by RT-Q-PCR (data not shown). Parthenolide is a natural product isolated from the medicinal herb Feverfew that can inhibit NF-kB by directly binding to and inhibiting IkB kinase (Kwok et al., 2001) . Treatment with 5 mM parthenolide significantly inhibited NF-kB reporter activity (Po0.01) but activated both AP-1 reporter (Po0.05) and STAT reporter (n.s.) activities (Figure 6b ). Our observation of JNK activation by parthenolide was consistent with a previous report that parthenolide could activate JNK in addition to an independent inhibition of NF-kB activity (Nakshatri et al., 2004) . Although it remains unclear whether STAT3 activation by parthenolide was dependent on or independent of JNK activation, the concurrent activation of both JNK and STAT3, when NF-kB activity was inhibited, ruled out a positive role of NF-kB for the activation of STAT3 in BR cells treated with 1 mM paclitaxel. Furthermore, dominant-negative (dn) JNK significantly inhibited both the AP1 and STAT reporter activation induced by 1 mM paclitaxel, but did not inhibit those activated by 50 mM paclitaxel (Figure 6c ).
Taken together, these results indicated that two pathways ( Figure 7 ) are involved in the upregulation of IL-6 by treatment with paclitaxel: (a) at low, pharmacological concentrations (exemplified by 1 mM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation, and (b) at high, suprapharmacological concentrations (exemplified by 50 mM in this study), paclitaxel exerted LPS-like effects, which were most likely carried out through the TLR4 signaling pathway as reported previously (Kawasaki et al., 2000 (Kawasaki et al., , 2003 Perera et al., 2001 ).
Discussion
The paclitaxel-activated JNK signaling pathway has been correlated with tumor cell death in many types of ovarian cancer (Lee et al., 1996; Wang et al., 1999 Wang et al., , 1998 MacKeigan et al., 2000) , breast cancer (Wang et al., 1998; MacKeigan et al., 2000) and lung cancer (MacKeigan et al., 2000) , suggesting that it may be a common mechanism of chemotherapy. Using DNA microarray (from 4 to 1625 pg/1000 cells in 24 h, as specified in parentheses) IL-6 into culture media. Secretion of IL-6 in ovarian cancer cells could be increased 2 to 3.2-fold by treatment with 1 mM PTX for 24 h. The only ovarian cancer line that did not secrete detectable basal or stimulated levels of IL-6 was TOV-112D. (c) Treatment with 1 mM PTX activated 3.3-fold STAT3 reporter, which could be either knocked down by the siRNA specific for IL-6 (k/d IL-6) or inhibited by co-treatment with 10 mM SP600125 (SP), a c-Jun Nterminal kinase (JNK) inhibitor. All fold changes were normalized with the STAT3 activity in dimethylsulphoxide-treated BR cells, which was set at onefold. (d) With or without co-treatment with 10 mM SP600125 (SP) and knocking down of JNK1 with shRNA, BR cells were treated with 0, 1, 10 and 50 mM paclitaxel (PTX) as indicated for 24 h, and the secretion of IL-6 into culture media was measured with enzyme-linked immunosorbant assay. All results shown were obtained from three independent experiments and represented as mean7standard error (s.e.m.).
analysis of the changes of gene expression in BR ovarian cancer cells treated with 1 mM paclitaxel in the presence or absence of the JNK inhibitor SP600125 (Figure 3 ), we have identified 14 genes significantly upregulated and six genes downregulated by the activated JNK signaling pathway (Table 1) . Possible functions of these 20 genes are involved in the regulation of cytoskeleton function (LAMA3, KRT14, EMP1, ABLIM1, KNS2 and TAGLN), cell growth and differentiation (HBP17, RAI3, TLE1 and HOXA4), regulation of apoptosis (IL-6, CNR2 and ICAM2), as well as other functions Biphasic dose-dependent activation of AP1, NF-kB and STAT3 reporter by treatment with paclitaxel (PTX). BR cells were transfected with plasmid DNA for AP1-luciferase reporter (a), NFkB-luciferase reporter (b) and STAT3-luciferase reporter (c), followed by treatment with 0.1 to 50 mM PTX as indicated, and were assayed for luciferase activities. Statistic significance (Po0.05) is indicated by pairs of # and * followed by a number; n.s. represents no statistical significance. Results shown were obtained from three independent experiments and are presented as mean7standard error (s.e.m.). All fold changes were normalized with the specified reporter activity in c-Jun N-terminal kinasetreated BR cells (shown as 0 mM PTX), which was set as 1.
TLR4
MyD88 NF-IL6 Genes (FLOT1, HSIT2H2B, MT1F, TERF1, DSIPI, MYEOV and CIB1). Many of these genes have not been previously associated with paclitaxel-induced apoptosis and hence are worth further study. Increased serum levels of IL-6 in patients with lung cancer were proposed as reflection of an immune response of cancer patients (healthy subjects 23.1471.88 pg/ml; lung cancer patients 60.5376.27 pg/ ml, P ¼ 0.003) (Brichory et al., 2001) . However, in the absence of immune cells, we identified the 24-h secretion amounts of IL-6 in 87.5% of eight ovarian cancer cell lines to be from 4 to 1625 pg/1000 cells (mean ¼ 482, median ¼ 130 pg/1000 cells) (Figure 4b ). Our demonstration of IL-6 production by ovarian cancer cells is in agreement with previous findings (Watson et al., 1990; Li et al., 1992) . Results of this study further indicated that paclitaxel stimulated the dose-dependent secretion of functional IL-6 into culture media (Figure 4) . As IL-6 has been suggested to play a positive role in cell cycle promotion and/or apoptosis inhibition in ovarian cancer cells (Penson et al., 2000; Hefler et al., 2003; Liu et al., 2004) as well as in various types of other cancers (Baffet et al., 1991; Villunger et al., 1996; Sriuranpong et al., 2003; Wei et al., 2003) , upregulation of IL-6 in BR cells upon treatment with paclitaxel could be one potential mechanism of the previously proposed drug resistances (Duan et al., 1999; Yusuf et al., 2003) .
At clinically achievable concentrations, usually less than 3 mM, paclitaxel effects were believed to depend on its microtubule-binding property (Blagosklonny and Fojo, 1999) . Our previous studies reinforced this conclusion (Wang et al., 1999 (Wang et al., , 1998 (Wang et al., , 2000 . Results of this study demonstrated that paclitaxel in this range of concentrations activated IL-6 through the activation of JNK signaling pathway but not through the LPS-like activity of paclitaxel. First, the 1 mM concentration of paclitaxel used in this study was much lower than that reportedly (3-140 mM) effective for upregulation of IL1alpha, IL-1 beta, IL-8 and TNF-alpha (Ding et al., 1990; Lee et al., 1996; Lanni et al., 1997; Kawasaki et al., 2000 Kawasaki et al., , 2003 Perera et al., 2001; Takeda et al., 2003) . Second, no upregulation of TLR4, MyD88, or NF-IL6 in terms of mRNA levels in BR cells treated with 1 mM paclitaxel was noted (Figure 6a ). Third, cotreatment of BR cells with 5 mM parthenolide (an IKK inhibitor) inhibited the paclitaxel-activated NF-kB reporter without decreasing AP1 and STAT3 activities, further diminishing the positive role of NF-kB in upregulating IL-6 at 1 mM concentration of paclitaxel (Figure 6b ). Lastly, a dominant negative expression vector for JNK significantly inhibited the activation of both AP1 and STAT3 reporter by 1 mM paclitaxel but did not inhibit their activation induced by 50 mM paclitaxel (Figure 6c) .
At high concentrations (5-30 mM), paclitaxel has been reported to exert endotoxin LPS-like effects through treatment on macrophage-like cells, including the upregulation of various cytokines (Ding et al., 1990; Lee et al., 1996; Lanni et al., 1997) . Lipopolysaccharidelike effects of paclitaxel were thought to be conveyed through TNF receptor (Ding et al., 1990) or TLR-4 (Kawasaki et al., 2000 (Kawasaki et al., , 2003 Perera et al., 2001) . Microtubule cytoskeleton dysfunction has been shown to activate NF-kB (Rosette and Karin, 1995; Das and Mechanisms of IL-6 upregulation by paclitaxel T-H Wang et al White, 1997) . Most recent reports have suggested activation of NF-kB to be an antiapoptotic mechanism of cancer cells (Dong et al., 2002; Uzzo et al., 2002; Dey et al., 2003; Flynn et al., 2003; Lin et al., 2004) , although contrary observations have also been reported (Huang and Fan, 2002) . Notably, NF-kB is also an important downstream transcription factor in the TLR4-MyD88 signaling cascade (Takeda et al., 2003) ( Figure 7 ). In our study, paclitaxel from 0.1 to 50 mM elicited a biphasic dose-dependent reporter activation for AP1, NF-kB and STAT3 (Figure 5 ), suggesting that the paclitaxel at suprapharmacologically high concentrations might elicit LPS-like effects, and may upregulate IL-6 through the TLR4-NF-kB cascade in BR ovarian cancer cells. Collectively, our results suggested more than one pathway to be involved in the upregulation of IL-6 depending on the concentration of paclitaxel. At pharmacologically low concentrations (exemplified by 1 mM in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation. However, at suprapharmacologically high concentrations (exemplified by 50 mM in this study), paclitaxel exerted LPS-like effects likely through the TLR4 signaling pathway as reported previously (Kawasaki et al., 2000 (Kawasaki et al., , 2003 Perera et al., 2001) . Elucidation of the signaling networks that are differentially initiated by low concentrations or by high concentrations of paclitaxel and the verification of specific inhibitors against key molecules inside the networks may help us in developing a better chemotherapeutic strategy in treatment of ovarian cancer with paclitaxel. Practically, paclitaxel at doses higher than necessary may elicit unwanted upregulation of IL-6, which may induce adverse side effects of chemotherapy (Pusztai et al., 2004) and increase the chance of cancer cells developing drug resistances (Duan et al., 1999) . Our understanding of the multiple paclitaxel dose-dependent signaling pathways involved in the upregulation of IL-6 is of clinical importance because these results suggest that fine-tuning the therapeutic concentrations of paclitaxel in patients may be crucial for avoiding undesired effects.
Materials and methods
Cell culture and treatment
Human ovarian cancer cell line BR cells were cultured in DMEM-F12 medium with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 U/ml), at 371C in a 5% CO 2 atmosphere as described previously (Wang et al., 1998 (Wang et al., , 1999 . Additional seven ovarian cancer cell lines, Caov3, MDAH 2774, SKOV-3, TOV-21G, TOV-112D, OV-90 and OVCAR-3, were obtained from the ATCC (Rockville, MD, USA). At about 70% confluence, BR cells were treated with paclitaxel (Sigma-Aldrich, St Louis, MO, USA), a specific JNK inhibitor SP600125 (Bennett et al., 2001) (Tocris Cookson, Bristol, UK) or an NF-kB inhibitor parthenolide (Kwok et al., 2001 ) (Sigma-Aldrich) at concentrations as indicated. Paclitaxel, SP600125 and parthenolide were dissolved in dimethylsulphoxide (DMSO). Hence when served as controls in this study, ovarian cancer cells were treated with comparable concentrations of DMSO.
Assays of cell survival and apoptosis
The number of survived BR cells before and after chemical treatments was evaluated by cell counting of 0.4% Trypan blue-excluding cells with hemocytometer and by MTT assay. Apoptosis was assessed by immunoblotting for the cleavage of PARP (Wang et al., 1999) and TUNEL assay (Roche Applied Science, Indianapolis, IN USA) on BR cells growing on chamber slides (Nalge Nunc International, Rochester, NY USA) before and after treatments. For TUNEL assay, cells were counterstained with hematoxylin (Sigma-Aldrich) for 20 s, covered with coverslips and examined under light microscopy.
Flow cytometry analysis of the cell cycle After indicated treatments, BR cells were trypsinized, rinsed with ice-cold phosphate-buffered saline (PBS, pH 7.4) and fixed with 70% ethanol at 41C overnight. Before flow cytometric assays, fixed cells were resuspended in PBScontaining 0.1 mg/ml RNAase at room temperature for 30 min before propidium iodide (Sigma-Aldrich) was added to the final 20 mg/ml concentration. Cell suspensions were filtered through a 40 mm filter and analysed for the cell cycle profile with FACSCalibur flow cytometry system (BD Biosciences, Franklin Lakes, NJ, USA).
Immunoblotting for c-Jun N-terminal kinase, c-Jun and poly (ADP-ribose) polymerase After indicated treatments, BR cells on culture dishes were rinsed once with ice-cold PBS (pH 7.4) and lysed for 30 min in lysis buffer (20 mM Tris pH 7.4, 200 mM NaCl, 0.1% NP-40, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonylfluoride and 10 mM NaF). Cell lysates were clarified by centrifugation at 41C for 10 min at 12 000 g. Protein concentration of the lysates was measured with the Bradford methods (Bio-Rad), and equal amounts of total protein were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA). Nitrocellulose membranes were blocked with Tris-buffered saline-containing 0.05% Tween 20 and 5% non-fat dry milk at room temperature for 60 min before incubated with specific antibodies. Specific antibodies used in this study were anti-JNK1 (Santa Cruz, Santa Cruz, CA, USA #SC-474), anti-phosphorylated JNK (Cell Signaling Technology, Inc., 3 Trask Lane, Danvers, MA 01923, USA #9251), anti-c-Jun (Cell Signaling, #9262), anti-phosphorylated c-Jun (Cell Signaling, #9261), anti-beta actin (Santa Cruz, #1616), anti-PARP (Cell Signaling, #9542) and various horseradish peroxidase-conjugated secondary antibodies (Santa Cruz). Bound antibodies were visualized using the enhanced chemiluminescence system (Amersham Bioscience).
Enzyme-linked immunosorbant assay of interleukin-6
The levels of IL-6 secreted by paclitaxel-treated ovarian cancer cells into culture medium were measured with Human IL-6 Biotrak enzyme-linked immunosorbant assay (ELISA) system (Amersham Bioscience, #RPN2784) according to the manufacturer's protocol. Ovarian cancer cells were cultured up to 80% confluent before they were treated with 0.1-50 mM paclitaxel for 24 h, and culture media were stored at À801C till measurement of IL-6. For comparing the 24-h IL-6 secretion amounts between ovarian cancer cell lines, the numbers of individual paclitaxel-treated cells were recorded at the end of 24-h treatment and used for normalization.
RNA extraction and real-time quantitative PCR
Total RNA from treated BR cells was isolated with RNA Bee reagents (Tel-Test Inc., Friendswood, TX, USA) and further purified with RNAeasy Mini kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturers' protocols. Quality and quantity of total RNA were evaluated with Agilent Bioanalyzer 2100 (CA, USA). To determine the gene expression changes of selected genes along with a time course of paclitaxel treatment, RT-Q-PCR was carried out in ABI 7900 HT RT-PCR system (Applied Biosystems, Foster City, CA, USA) using Assay-on-Demand TaqMan probe sets (Applied Biosystems) according to the manufacturer's protocol. In RNA specimens isolated from BR cells in 2-4 independent paclitaxel-treatment experiments, each reaction was carried out in duplicate and the relative quantitation of gene expression was calculated using the comparative C T method (Livak and Schmittgen, 2001 ). The expression level of glyceraldehydes 3 phosphate dehydrogenase was used as an internal control for gene expression.
Analysis of gene expression with human cDNA microarrays Twenty microgram total RNA was used for labeling and hybridization with the 3DNA 300Array Detection kit (Genisphere, PA, USA), and slides were scanned with a confocal scanner ChipReader (Virtek, Canada). Spot and background intensities were acquired with GenePix Pro 4.1 software (Axon Instruments Inc., CA, USA). To carry out within-slide normalization, the local weighted regress (Lowess) method was used where changes of intensity were assumed to be symmetric for all spots; thus, normalization was performed in each bin of spots. The software and instructions for performing Lowess algorithm were obtained from www.stat. berkeley.edu/users/terry/zarray/Html/soft.htm. After normalization, we averaged four replicated log ratios of each gene (two from duplicates on the slide and other two from dyeswapping) and performed Student's t-test on each gene between indicated groups. The gene-specific t-test was not affected by heterogeneity in variance across genes because it only used information from one gene at a time (Cui and Churchill, 2003) .
Transfection of ovarian cancer cells and luciferase reporter assay BR cells were transfected with AP1-luciferase reporter, STAT3-luciferase reporter (both from Panomics, CA, USA) or NF-kB-luciferase reporter (kindly provided by Dr Z-G Liu, NIH, MD, USA) (Liu et al., 1996) using Effectene Transfection Reagent (Qiagen) according to the manufacturer's protocols. Knockdown of the expression in IL-6 and JNK1 (MAPK8) was achieved by RNA interference with shRNA expression vectors (Open Biosystems, Huntsville, AL, USA). Twenty four hours after transfection, cells were rinsed once with PBS, the medium was changed and they were then treated with 1 mM paclitaxel for indicated time before either IL6 quantitation with ELISA or reporter assays with luciferase assay reagents (Promega, WI, USA) on Victor 2 Wallach spectrometer (EG&G Instruments, Gaithersburg, MD, USA). For each reporter assay, potential variations of transfection efficiency were minimized by co-transfecting cells with pSV-b-galactosidase control vector (Promega, USA) and normalizing luciferase readings by b-galactosidase activity. Dominant-negative expression vector for JNK was previously reported (Wang et al., 1998 (Wang et al., , 1999 .
